Literature DB >> 22153822

Remote treatment of intermittent central suppression improves quality-of-life measures.

Eric S Hussey1.   

Abstract

BACKGROUND: Intermittent central suppression (ICS) is a repetitive intermittent ("on-and-off") loss of central visual sensation without strabismus or amblyopia. These repetitive seconds-long suppressions have been suggested to create visual confusion and instability that would cause vision symptoms, contribute to reading complaints, and even impair reading.
METHODS: Teacher-identified Job Corps students were diagnosed with ICS and then treated with 5-Hz electronic liquid crystal shutter alternate occlusion.
RESULTS: Twenty-six young adult students (19.7±1.6 y) had their ICS treated over 5.9±3.7 months. Suppression periods decreased in length (P<0.0001) and "binocular" nonsuppressed periods increased in length (P<0.0001). Overall, College of Optometrists in Vision Development (COVD) quality-of-life (QOL) scores improved (P<0.0001), 16 reading behavior COVD QOL questions improved (P<0.0001), and individual QOL questions improved. Posttherapy reading scores (N=18) improved 3.7 (±2.6) years (P<0.0001).
CONCLUSIONS: Treating ICS with electronic alternate occlusion reduced suppression periods, increased binocular periods, and improved symptoms as measured in the COVD QOL questionnaire. Positive changes also occurred in reading scores. These data suggest ICS should be considered a probable cause for symptoms of reading problems.
Copyright © 2012 American Optometric Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22153822     DOI: 10.1016/j.optm.2011.05.009

Source DB:  PubMed          Journal:  Optometry        ISSN: 1558-1527


  1 in total

1.  Alternative Flicker Glass: A New Anti-Suppression Approach to the Treatment of Anisometropic Amblyopia.

Authors:  Ying Yuan; Chengcheng Zhu; Peng Wang; Xiaojun Hu; Wenbo Yao; Xinhui Huang; Bilian Ke
Journal:  Ophthalmic Res       Date:  2021-03-02       Impact factor: 2.892

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.